NOTE 13 - SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 13 — SUBSEQUENT EVENTS

Subsequent common stock issuances

In October and November 2016, the Company issued an aggregate of 29,511,799 and 848,490 shares of its common stock in settlement of $37,950 notes payable and six months interest totaling $12,705 on Northstar note payable. 

On August 30^th, 2016 Northstar Biotech Group, LLC (“NorthStar”) filed suit against the Company, of which the Company received notice several weeks later. In its suit, Northstar is seeking  a declaratory judgment from the Court as to whether its preferred shares were the subject of the Company’s reverse stock split effective November 4, 2015 and also seeks the appointment of a receiver. Northstar did not seek money damages. The Company disputes Northstar’s claims and intends to vigorously defend this matter.

On November 7, 2016, the Board of Directors, formed a separate committee to review and advise on improper activities undertaken by Charles Hart both during his tenure as a member of the Board of Directors and subsequent to his termination from the Board of Directors, specifically during the ninety days following his termination in which he is still considered an affiliate of the Company. Charles Hart was a member of the Board of Directors of NorthStar and is, to our knowledge, is no longer a Director but remains a Member of the closely held NorthStar Biotech Group, LLC. (See the Current Report on Form 8-K, filed with the Securities and Exchange Committee on August 2, 2016, reporting that on August 1, 2016, Charles Hart was removed as a member of the Board of Directors).